TCV−116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats
- 31 December 1994
- journal article
- Published by Elsevier in Life Sciences
- Vol. 54 (25) , 1987-1994
- https://doi.org/10.1016/0024-3205(94)90133-3
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive ratsLife Sciences, 1992
- Direct evidence for local generation and release of angiotensin II in human vascular tissueBiochemical and Biophysical Research Communications, 1989
- Suppression of angiotensin II release by prostaglandin synthesis inhibitors in hind legs.Hypertension, 1988
- Local generation and release of angiotensin II in peripheral vascular tissue.Hypertension, 1988
- Plasma norepinephrine and left ventricular hypertrophy in systemic hypertensionThe American Journal of Cardiology, 1984
- Editorial note Antihypertensive treatment and regression of left ventricular hypertrophyInternational Journal of Cardiology, 1984
- A very sensitive direct radioimmunoassay system for plasma angiotensin II and its clinical application in various hypertensive diseases.Japanese Circulation Journal, 1984
- Collagen synthesis in development and reversal of cardiac hypertrophy in spontaneously hypertensive ratsThe American Journal of Cardiology, 1979
- Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy?The American Journal of Cardiology, 1979
- Aspects of cardiac hypertrophyAmerican Heart Journal, 1953